• Thomas Etergino has resigned as vice president and CFO of AtriCure (West Chester, Ohio). Until a successor is named, David Drachman, president/CEO, will manage company finances. AtriCure develops surgical devices that create precise lesions in soft and cardiac tissues.

• Cambridge Heart (Bedford, Massachusetts) has hired Mark Florence as vice president, sales and marketing. Most recently Florence was vice president of sales at CardioDynamics. Robert LaRoche, former vice president, sales and marketing, has left the company to pursue other interests. Cambridge Heart develops products for the noninvasive diagnosis of cardiac disease.

• Michael Adams has been named president/CEO of CardioTech International (Wilmington, Massachusetts), replacing Dr. Michael Szycher. Adams has been serving as vice president of regulatory affairs and business development and will continue to serve in those capacities. CardioTech’s board of directors also appointed William O’Neill as its new chairman. O’Neill has served on the company’s board of directors since 2004 CardioTech manufactures products for the treatment of cardiovascular, orthopedic, oncology and other diseases. Its flagship product is CardioPass, a synthetic coronary artery bypass graft.

• Alan Totah has joined MicroMed Cardiovascular (Houston) as senior vice president, regulatory affairs and quality systems. Totah previously served as vice president of regulatory affairs and quality systems for Cyberonics. MicroMed makes heart failure products, including the DeBakey VAD (ventricular-assist device) for the treatment of advanced heart failure.

• Tony Chou, MD, has joined The Vertical Group (Summit, New Jersey), a medical technology venture capital firm, as a venture partner in its Palo Alto, California, office. Chou is an interventional cardiologist and formerly vice president and general manager of the Abbott Vascular division of Abbott Laboratories. During his tenure at Abbott, Chou managed the IDE study, PMA process and the global launch of the StarClose femoral closure device and was a member of the business development team that executed Abbott Vascular’s strategic transactions, including an alliance with Medtronic covering drug-eluting stent technology and the acquisitions of Integrated Vascular Systems, Mednova, the Jomed cardiovascular assets and the Biocompatibles cardiovascular franchise.